Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etanercept + adalimumab + infliximab + certolizumab + golimumab + tozilizumab + abatacept-Medical University of Graz
- Development stage
- Unknown
- Lead developer
- Medical University Graz
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
This entry refers to a specific group of biologic disease-modifying antirheumatic drugs (bDMARDs) evaluated in the clinical trial NCT01602302, conducted by the Medical University of Graz. The study, titled 'Ultrasound for bDMARD Withdrawal in RA,' investigated whether musculoskeletal ultrasound could serve as a biomarker to predict disease flares in rheumatoid arthritis patients who discontinued their biologic therapy after achieving persistent clinical remission. The group includes five TNF-alpha inhibitors (etanercept, adalimumab, infliximab, certolizumab pegol, and golimumab), an IL-6 receptor antagonist (tocilizumab), and a T-cell costimulation modulator (abatacept). These drugs represent the standard of care for patients with moderate-to-severe rheumatoid arthritis who have an inadequate response to synthetic DMARDs.
- Brand names
- ActemraOrencia
- Other names
- bDMARDsbiological DMARDsbiological disease-modifying antirheumatic drugs
02
Targets
NeuraminidaseIL-6R (Interleukin-6 receptor subunit alpha)TNFA (Tumor necrosis factor alpha (soluble))LTA (Lymphotoxin-alpha)CD80 (T-lymphocyte activation antigen CD80)CD86 (T-lymphocyte activation antigen CD86)
Beyond the preview
Go deeper on etanercept + adalimumab + infliximab + certolizumab + golimumab + tozilizumab + abatacept-Medical University of Graz.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etanercept + adalimumab + infliximab + certolizumab + golimumab + tozilizumab + abatacept-Medical University of Graz.